Is Hyatt Hotels Corporation (H) a Buy in April 2026?

GE HealthCare Technologies Inc. currently trades at a trailing twelve-month P/E ratio of 22.01x, modestly above its own 3-year historical average of 20.37x, yet meaningfully below the industry average of 31.57x. The premium to its own history reflects either a modest re-rating by the market or transient earnings compression suppressing the denominator, while the substantial discount to peers — approximately 30% — is a notable divergence that warrants scrutiny rather than automatic dismissal.

On a P/E basis, GEHC screens as tentatively undervalued relative to the broader medical technology peer group. The discount to the industry average is large enough to represent a genuine valuation opportunity if earnings normalize, though the divergence between current and historical margins, discussed below, introduces meaningful uncertainty around the earnings base. Signal: Cautiously Constructive.

GE HealthCare Technologies Inc. carries a current TTM Price-to-Sales ratio of 1.89x, which is precisely in line with its 3-year historical average of 1.89x, indicating near-zero multiple expansion or contraction on a revenue basis since the spin-off. Against an industry average of 2.91x, GEHC trades at a 35% discount on this metric, suggesting the market ascribes materially lower revenue quality or growth optionality to GEHC relative to sector peers.

The static nature of the P/S multiple — unchanged from the historical mean — implies the stock has largely tracked revenue growth without commanding any incremental premium. The persistent discount to industry on a sales basis reinforces the view that GEHC has not yet earned a premium multiple in the post-spin era. Signal: Neutral to Mildly Constructive, contingent on margin recovery.

GE HealthCare Technologies Inc. trades at a TTM Price-to-Free Cash Flow multiple of 24.56x, modestly above its 3-year historical average of 23.17x and at a premium to the industry average of 21.89x. This above-market P/FCF multiple is somewhat counterintuitive given the discounts observed on P/E and P/S, and suggests that while reported earnings and revenues are being discounted by the market, investors assign relatively higher confidence to the company’s free cash flow generation capacity.

The P/FCF premium to both history and industry peers implies GEHC’s free cash flow is perceived as higher quality or more durable than its net income line would suggest — a reasonable interpretation given the margin compression visible in the profitability data. However, the slight premium to peers on this metric limits the upside argument from a cash flow valuation standpoint. Signal: Neutral; FCF multiple premium caps near-term re-rating potential on this axis.

On a Price-to-Operating Cash Flow basis, GE HealthCare Technologies Inc. trades at 18.60x TTM, marginally above its 3-year historical average of 18.48x and at a premium to the industry average of 16.53x. The consistency between current and historical P/OCF multiples reinforces the picture of a company whose operating cash conversion has remained relatively stable even as net margins have deteriorated.

The approximately 13% premium to the industry average on P/OCF is a modest headwind to a purely valuation-driven bull case. It signals that on an operating cash flow basis, GEHC is not cheap relative to peers, and that the apparent valuation discount on earnings and revenue multiples does not fully carry through to cash flow metrics. Signal: Mildly Cautious; OCF premium to peers warrants monitoring.

GE HealthCare Technologies Inc. reports a TTM net margin of 3.94%, a significant deterioration from its 3-year historical average of 8.86% and well below the industry average of 9.45%. The compression of approximately 490 basis points from the company’s own historical baseline — and a roughly 550 basis point gap to the peer group — is the single most important fundamental concern in this analysis. The magnitude of the decline is not consistent with normal cyclical fluctuation and demands explanation at the earnings level.

The sharp margin contraction, particularly visible in the most recent quarterly data where net profit dropped to $184 million on $4.67 billion in revenue, implies the presence of one-time charges, restructuring costs, elevated input costs, or accelerating SG&A and R&D investment. Until management provides a credible path back toward the 8–9% margin corridor, the earnings multiple discount relative to peers is partially justified. Signal: Cautious; margin recovery is the critical catalyst for re-rating.

GE HealthCare Technologies Inc. carries a TTM Debt-to-Equity ratio of 0.96x, an improvement from its 3-year historical average of 1.24x, reflecting active deleveraging since the spin-off from General Electric. The industry average of -0.87x is anomalous and likely reflects a peer set with significant net cash positions or negative book equity distortions, making direct comparison on this metric less instructive than the trend in GEHC’s own leverage trajectory.

The directional improvement in the D/E ratio from 1.24x to 0.96x over the observable period is a constructive development, signaling management’s commitment to balance sheet normalization post-spin. A sub-1.0x D/E ratio, while still carrying meaningful absolute leverage, reduces refinancing risk and preserves financial flexibility for capital allocation. Signal: Constructive; continued deleveraging trajectory supports credit quality improvement.

Across the eight reported quarters, GE HealthCare Technologies Inc. generated revenues ranging from approximately $4.65 billion to $5.32 billion, with the TTM revenue base implying a mid-single-digit compound growth rate. The revenue trajectory is broadly positive, with Q4 of the first observed year reaching a peak of $5.32 billion before moderating in subsequent periods. Net profit, however, tells a more volatile story: rising from $374 million in Q1 to a peak of $720 million in Q4 of year one, before declining sharply to $184 million in the most recent quarter — the lowest profit print across the entire observed window.

The divergence between relatively stable revenue and sharply declining profitability in the most recent period is the defining characteristic of this growth trajectory. Revenue resilience affirms the durability of GEHC’s end-market demand and installed-base economics, but the profit deterioration introduces execution risk and raises questions about cost discipline, pricing power, or the presence of non-recurring charges. Institutional investors should weight the most recent quarter’s profit figure carefully — if idiosyncratic, the stock screens attractively; if structural, downside earnings revisions are likely. Signal: Mixed; revenue trajectory is stable, but profit volatility is a near-term overhang.

GE HealthCare Technologies Inc. currently trades at $72.26 per share, representing a drawdown of approximately 23.0% from its all-time high of $93.87. For a company that has been publicly traded as an independent entity only since early 2023, reaching an all-time high and then retracing nearly a quarter of that peak value within a compressed timeframe reflects either broad sector multiple compression, company-specific fundamental deterioration, or a combination of both.

A 23% drawdown from peak, when contextualized alongside the margin compression and earnings volatility observed in the fundamental data, suggests the market has already begun pricing in near-term operational headwinds. From a mean-reversion and technical standpoint, GEHC is trading in a range that has historically represented an entry point for long-horizon institutional accumulators in high-quality medtech franchises — provided the earnings degradation proves transient. Signal: Tentatively Constructive from a positioning standpoint; risk-reward improves materially if margin normalization is confirmed.